{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117257","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.129776+00:00","generated_at":"2026-06-08T05:16:26.507491+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elutia Q3 net sales $6.1M (+5% YoY); proprietary products up 26%; narrows net loss; to file 510(k) for CanGarooRM in Q4","bullets":["Net loss from continuing ops $8.5M ($0.50/sh), improving from $11.0M ($0.81/sh) YoY.","Proprietary product sales (SimpliDerm +44%, CanGaroo +11% YoY) drove 26% overall proprietary growth; total net sales $6.1M.","Completed Orthobiologics divestiture for initial $15M, plus private placement netting $10.5M; cash balance $14.5M at Sept 30.","Anticipates FDA 510(k) filing for CanGarooRM by year-end 2023, targeting $600M drug-eluting CIED envelope market.","Operating expenses down 14% YoY to $10.2M; gross margin declined to 46.4% from 50.2% due to distributor pricing shift."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117257","json":"https://secwatch.observer/filing/0001104659-23-117257.json","markdown":"https://secwatch.observer/filing/0001104659-23-117257.md","text":"https://secwatch.observer/filing/0001104659-23-117257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/0001104659-23-117257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/tm2330559d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:16:26.507491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d86729c2f74a8f781072e8ebca330298fb0cea85","claim":"ELUTIA INC. reported third quarter ended September 30, 2023 results: revenue $6.1 million, net income $8.5 million, EPS $0.50 per share.","evidence_excerpt":"and minocycline, we believe CanGarooRM is well-positioned to compete effectively in this space. Third Quarter 2023 Financial Results Net sales for the third quarter of 2023 were $6.1 million, compared to $5.8 million in the third quarter of 2022. Net sales of both SimpliDerm and CanGaroo performed well, growing 44% and 11%, respectively, versus the third quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708527/000110465923117257/0001104659-23-117257-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$6.1 million"},{"label":"Net income","value":"$8.5 million"},{"label":"EPS","value":"$0.50 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}